We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 120% below its sector, cheaper than its peers on earnings.
Excelsior Biopharma Inc., established in 1988 and headquartered in Taipei, Taiwan, functions as a pharmaceutical enterprise with a global market presence, encompassing Taiwan, China, and other international regions. The company offers a comprehensive range of healthcare solutions, including prescription and over-the-counter medications, medical devices, nutritional supplements, and various medical supplies. Excelsior addresses numerous therapeutic areas such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, otorhinolaryngology, and infectious disease management. Its product line also features specialized diagnostic kits under the Actim brand for identifying conditions like influenza virus, fecal occult blood, acute pancreatitis, and for assessing preterm or full-week delivery and early membrane rupture. Moreover, the company provides oral hygiene products, including toothpaste, mouthwash, and gels, under the Oral7 name. Beyond product sales, Excelsior is involved in the import and export of active pharmaceutical ingredients, as well as engaging in technological research, facilitating pharmaceutical technology transfer, and participating in collaborative development and improvement initiatives. The company adopted its current name, Excelsior Biopharma Inc., in June 2003, having previously been known as Excelsior Enterprise Co., Ltd.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6496.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.